Should You Buy Lockheed Martin While It's Up 26% in 2026?

Lockheed reported Q4 2025 sales growth of 6% and a backlog of $194 billion, with free cash flow above expectations; shares are up over 26% YTD in 2026. Management guides to roughly 5% sales growth and 25% segment operating growth for 2026, and the dividend yield is about 2.2%. Valuation risks are rising — trailing P/E is nearing 30 and market cap rose from $104B to $144B over the past 12 months — which could cap upside despite favorable defense spending tailwinds.

Analysis

The market is pricing defense risk as binary — a high-probability fiscal tailwind versus execution risk — which magnifies the value of near-term contract optionality more than long-term fundamentals. That creates pockets of asymmetric return: primes with tight integration, in-house tooling and program control will see outsized margin expansion if award cadence accelerates, while highly outsourced platforms will suffer from supplier bottlenecks and bid defensiveness. Expect M&A and repricing in the mid-tier supply base as primes vertically reintegrate to stem schedule risk and capture buyout synergies, creating 6–18 month windows for takeover-driven reratings.

Key catalysts are procedural and idiosyncratic rather than macro: appropriations sequencing, Foreign Military Sales approvals and a handful of milestone deliveries will move multiples faster than quarterly sales beats. Conversely, fixed-price program overruns, surge inflation in composite/avionics supply and a pause in buybacks or dividend increases are credible near-term shock events that can re-rate the sector. Interest-rate pathway matters — any rapid move lower would disproportionately benefit high-visibility FCF names with stable backlog, while stickier rates will compress defense multiples and extend time-to-realize cash conversion.

From a portfolio construction perspective, the cleanest way to express the upside is to buy convexity around award cadence rather than naked equities — use option structures or pair trades to monetize the timeline mismatch between budgeting and execution. Hedge sizing should reflect a two-stage outcome: a high-upside scenario concentrated in the 6–18 month window and a low-probability negative tail where program slips and political headwinds drive double-digit drawdowns. Monitor three data points weekly: appropriations calendar, major FMS decisions, and supplier earnings commentary on backlog conversion and backlog burn rates.

Key Decisions for Investors

• Buy LMT via a covered-LEAP buy-write: acquire shares and sell 6–9 month calls 5–8% OTM to collect premium while holding a 12–18 month LEAP call (finance cost). Timeframe: 6–18 months. Risk/Reward: generates ~6–12% annualized income with upside capped near the short-call strike; downside protected by premium but equity risk remains if shares fall >10–15%.
• Directional options spread: buy LMT 12–18 month LEAP calls (10–20% OTM) and finance with selling nearer-term (3–9 month) calls ~10% OTM — a calendar/vertical hybrid. Timeframe: 12–18 months. Risk/Reward: limited max loss = net premium; target 2x–4x payoff if award cadence accelerates within 12 months, loss if catalysts delay beyond option horizons.
• Relative-value pair: long LMT / short NOC (equal notional) for 6–12 months to isolate program execution and supply-chain exposure. Timeframe: 6–12 months. Risk/Reward: target 8–15% relative outperformance if LMT converts backlog faster or benefits from FMS cadence; risk is both names rerating up or down with macro or surprise policy shifts.
• Tail hedge ahead of appropriations: buy LMT 6–9 month put spread (10%/20% OTM) to cap downside into key budget votes. Timeframe: 3–9 months. Risk/Reward: small premium cost (~1–2% portfolio) limits drawdown risk while preserving majority of upside if budget path clears.